#USA #Lund #pancreatic cancer #TFS HealthScience #Oncomatryx

TFS HealthScience Expands Collaboration with Oncomatryx

TFS HealthScience, a prominent global Contract Research Organization (CRO), is taking significant steps to bolster its collaborative efforts with Oncomatryx, a biopharmaceutical entity focused on the development of innovative antibody-drug conjugates (ADCs). The collaboration aims to support a newly launched Phase Ib clinical trial that will assess OMTX705, an anti-fibroblast activation protein (FAP) antibody-drug conjugate targeting advanced pancreatic adenocarcinoma.

The clinical trial is set to be conducted at various sites across Spain and the United States, marking a significant milestone for both organizations as they strive for breakthroughs in oncology. According to the World Cancer Research Foundation, pancreatic cancer is one of the most lethal forms of cancer in the world, contributing to over 510,000 new cases and more than 466,000 deaths each year. Despite advancements in treatment options, patients suffering from advanced or metastatic forms of this disease still face limited alternatives, with the five-year survival rate stubbornly remaining below 10%.

This Phase Ib study is a continuation of a previous partnership between TFS and Oncomatryx, which was established during an earlier Phase I trial. That trial explored OMTX705 as a standalone treatment and in conjunction with pembrolizumab for patients with advanced solid tumors. The encouraging results from the initial study have laid the groundwork for the next phase of development, highlighting the essential qualities TFS brings to the partnership, including deep therapeutic expertise and a robust focus on oncology.

Kris O'Brien, Vice President and Head of Oncology & Rare Diseases at TFS, expressed the importance of this collaboration, saying, "Our ongoing work with Oncomatryx underscores our joint commitment to hastening the advancement of groundbreaking therapies for challenging cancer types such as pancreatic adenocarcinoma. TFS contributes unparalleled therapeutic insights and operational flexibility, facilitating the progression of promising scientific endeavors where they are most critical."

Laureano Simón, CEO of Oncomatryx, shared his excitement about moving into this new clinical development phase for OMTX705, remarking that TFS has proven to be a trusted partner, instrumental in advancing their scientific initiatives toward patients who desperately need new treatment options.

With two decades of experience in oncology research, TFS has supported numerous clinical trials covering a range of solid tumors, hematological malignancies, and rare cancers. Their approach is grounded in agility, scientific integrity, and an extensive global footprint, which has enabled the organization to guide various oncology programs from initial ideas to clinical practice effectively.

Backed by a solid financial foundation following a €25 million fundraising effort concluded at the end of 2024, the OMTX705 program is enjoying a surge in momentum. The anticipated Phase I clinical trial data is expected to be presented at key oncology conferences throughout 2025, further promoting the program's promise as a potential therapy for difficult-to-treat tumors, including pancreatic adenocarcinoma.

About TFS HealthScience

TFS HealthScience is a full-service global Contract Research Organization that partners with biopharmaceutical companies to advance innovative treatments and enhance patient outcomes. With operations across 40 countries, TFS and its strategic partners offer tailored clinical development services in various specialized therapeutic areas, such as oncology, dermatology, and internal medicine. TFS excels in providing flexible solutions that combine extensive global reach with the advantages of a mid-sized CRO. For further information, visit www.tfscro.com.

About Oncomatryx

Oncomatryx specializes in developing proprietary antibody-drug conjugate platforms that specifically target Cancer-Associated Fibroblasts within the microenvironment of metastatic solid tumors. The company collaborates with esteemed universities, hospitals, and research institutions in both the USA and Europe. Results from Phase I clinical studies of their innovative ADC, OMTX705, which targets Fibroblast activation Protein (FAP), will be featured at major oncology conferences throughout 2025. For more details, visit www.oncomatryx.com.